Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
04 2022
Historique:
received: 11 05 2021
revised: 22 10 2021
accepted: 28 10 2021
pubmed: 18 11 2021
medline: 13 4 2022
entrez: 17 11 2021
Statut: ppublish

Résumé

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is increasingly used to treat patients with peritoneal cancer. A recent survey demonstrated considerable diversification of current practice of PIPAC raising issues of concern also regarding safety and efficacy. The study aim was to reach consensus on best practice of PIPAC treatment. Current practice was critically discussed during an expert meeting and the available evidence was scrutinized to elaborate a 33-item closed-ended questionnaire. All active PIPAC centers were then invited to participate in an online two-round Delphi process with 3 reminders at least. Consensus was defined a priori as >70% agreement for a minimal response rate of 70%. Forty-nine out of 57 invited PIPAC centers participated in Delphi 1 and 2 (86%). Overall, there was agreement for 21/33 items. Consensus was reached for important aspects like advanced OR ventilation system (91.8%), remote monitoring (95.9%), use of the PRGS (85.7%) and use of a safety checklist (98%). The drug regimens oxaliplatin (87.8%) and cisplatin/doxorubicin (81.6%) were both confirmed by the expert panel. Important controversies included number and location of Biopsies during repeated PIPAC and the combination of PIPAC with additional surgical procedures. This consensus statement aims to allow for safe and efficacious PIPAC treatment and to facilitate multi-center analyses of the results. Additional preclinical and clinical studies are needed to resolve the remaining controversies.

Sections du résumé

BACKGROUND
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is increasingly used to treat patients with peritoneal cancer. A recent survey demonstrated considerable diversification of current practice of PIPAC raising issues of concern also regarding safety and efficacy. The study aim was to reach consensus on best practice of PIPAC treatment.
METHODS
Current practice was critically discussed during an expert meeting and the available evidence was scrutinized to elaborate a 33-item closed-ended questionnaire. All active PIPAC centers were then invited to participate in an online two-round Delphi process with 3 reminders at least. Consensus was defined a priori as >70% agreement for a minimal response rate of 70%.
RESULTS
Forty-nine out of 57 invited PIPAC centers participated in Delphi 1 and 2 (86%). Overall, there was agreement for 21/33 items. Consensus was reached for important aspects like advanced OR ventilation system (91.8%), remote monitoring (95.9%), use of the PRGS (85.7%) and use of a safety checklist (98%). The drug regimens oxaliplatin (87.8%) and cisplatin/doxorubicin (81.6%) were both confirmed by the expert panel. Important controversies included number and location of Biopsies during repeated PIPAC and the combination of PIPAC with additional surgical procedures.
CONCLUSION
This consensus statement aims to allow for safe and efficacious PIPAC treatment and to facilitate multi-center analyses of the results. Additional preclinical and clinical studies are needed to resolve the remaining controversies.

Identifiants

pubmed: 34785087
pii: S0748-7983(21)00778-2
doi: 10.1016/j.ejso.2021.10.028
pii:
doi:

Substances chimiques

Aerosols 0
Oxaliplatin 04ZR38536J
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

789-794

Investigateurs

Julio Abba (J)
Adnane Afifi (A)
Michael Bau Mortensen (MB)
Aditi Bhatt (A)
Andreas Brandl (A)
Wim Ceelen (W)
Julien Coget (J)
Thomas Courvoiser (T)
Ignace H de Hingh (IH)
Jean-Baptiste Delhorme (JB)
Andrea di Giorgio (A)
Frederic Dumont (F)
Cecilia Escayola (C)
Clarisse Eveno (C)
Anne-Cécile Ezanno (AC)
Johan Gagnière (J)
Julio Galindo (J)
Torben Glatz (T)
Olivier Glehen (O)
Tarkan Jäger (T)
Vahan Kepenekian (V)
Vladimir M Khomyakov (VM)
Konstantinos Kothonidis (K)
Kuno Lehmann (K)
Craig Lynch (C)
Sanket Mehta (S)
Bogdan Moldovan (B)
Aviram Nissan (A)
David Orry (D)
Gloria Ortega Pérez (GO)
Brice Paquette (B)
Marius Paskonis (M)
Pompiliu Piso (P)
Marc Pocard (M)
Beat Rau (B)
Manuela Robella (M)
Shivendra Singh (S)
S P Somashekhar (SP)
Claudio Soravia (C)
Abelkader Taibi (A)
Jared Torkington (J)
Giuseppe Vizzielli (G)
Wouter Willaert (W)

Informations de copyright

Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors report no conflicts of interest relevant to this article.

Auteurs

Martin Hübner (M)

Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Switzerland. Electronic address: martin.hubner@chuv.ch.

Mohammad Alyami (M)

Department of General Surgery and Surgical Oncology, Oncology Center, King Khalid Hospital, Najran, Saudi Arabia.

Laurent Villeneuve (L)

Hospices Civils de Lyon, Hôpital Lyon Sud, Service de Recherche et d'Epidémiologie Cliniques, Pierre-Bénite, F-69495, France; Université Lyon-1, EA 3738 CICLY, Oullins Cedex, F-69921, France.

Delia Cortés-Guiral (D)

Department of General Surgery and Surgical Oncology, Oncology Center, King Khalid Hospital, Najran, Saudi Arabia.

Maciej Nowacki (M)

Chair and Department of Surgical Oncology, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun. Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital in Bydgoszcz. Bydgoszcz, Poland.

Jimmy So (J)

National University Hospital, Singapore.

Olivia Sgarbura (O)

Department of Surgical Oncology, Cancer Institute Montpellier (ICM), Montpellier, France; University of Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH